Combined Antiangiogenic Therapy and Immunotherapy Is Effective for Pancreatic Cancer With Mismatch Repair Proficiency but High Tumor Mutation Burden: A Case Report

Overview

Journal Pancreas

Specialty Gastroenterology

Date 2019 Oct 15

PMID 31609933

Citations 11

Authors

Mengni Chen

Shengli Yang

Li Fan

Lu Wu

Renwang Chen

Jian Chang

Jianli Hu

Affiliations

Soon will be listed here.

Abstract

Immunotherapy has been recommended as a second-line treatment only for high microsatellite instability or DNA mismatch repair deficiency advanced pancreatic cancer in National Comprehensive Cancer Network guidelines. Here, we report a case with a good response to immunotherapy in pancreatic cancer with mismatch repair proficiency. A 55-year-old woman diagnosed with pancreatic cancer cT4N1M1 (liver, lung) who harbored ERBB2 mutations with high tumor mutation burden (TMB) underwent multiple therapies and survived 19 months. A partial response in pancreatic cancer was observed when the patient was treated with combined antiangiogenic therapy and immunotherapy after a series of ineffective treatments. Neutrophil-to-lymphocyte ratio (NLR), a predictive marker of efficacy of immunotherapy, confirmed that immunotherapy resulted in the partial response in pancreatic cancer. To our knowledge, this is the first to report advanced pancreatic cancer with mismatch repair proficiency had a good response to immunotherapy, and this is the first to report an association between high blood-based TMB or NLR and improved clinical outcomes in pancreatic cancer. Therefore, TMB may also be a biomarker for immunotherapy of pancreatic cancer, and NLR may be a prospective predictive marker for efficacy of immunotherapy in pancreatic cancer.

Citing Articles

Targeting Triple NK Cell Suppression Mechanisms: A Comprehensive Review of Biomarkers in Pancreatic Cancer Therapy.

Fanijavadi S, Thomassen M, Jensen L Int J Mol Sci. 2025; 26(2).

PMID: 39859231 PMC: 11765000. DOI: 10.3390/ijms26020515.

Nucleotide metabolism in cancer cells fuels a UDP-driven macrophage cross-talk, promoting immunosuppression and immunotherapy resistance.

Scolaro T, Manco M, Pecqueux M, Amorim R, Trotta R, Van Acker H Nat Cancer. 2024; 5(8):1206-1226.

PMID: 38844817 PMC: 11358017. DOI: 10.1038/s43018-024-00771-8.

Case report: A case study on the treatment using icaritin soft capsules in combination with lenvatinib achieving impressive PR and stage reduction in unresectable locally progressive pancreatic cancer and a literature review.

Liu X, Yang F, Jia D, Dong X, Zhang Y, Wu Z Front Genet. 2023; 14:1167470.

PMID: 37152980 PMC: 10156971. DOI: 10.3389/fgene.2023.1167470.

Case Report: Partial response to single-agent pembrolizumab in a chemotherapy-resistant metastatic pancreatic cancer patient with a high tumor mutation burden.

Dai M, Sheng J, Zhang Q, Wang J, Fu Q, Liang T Front Oncol. 2023; 13:1118633.

PMID: 36937383 PMC: 10016350. DOI: 10.3389/fonc.2023.1118633.

Characterization of pancreatic cancer with ultra-low tumor mutational burden.

Imamura T, Ashida R, Ohshima K, Uesaka K, Sugiura T, Ohgi K Sci Rep. 2023; 13(1):4359.

PMID: 36928600 PMC: 10020557. DOI: 10.1038/s41598-023-31579-8.

References

Capone M, Giannarelli D, Mallardo D, Madonna G, Festino L, Grimaldi A . Baseline neutrophil-to-lymphocyte ratio (NLR) and derived NLR could predict overall survival in patients with advanced melanoma treated with nivolumab. J Immunother Cancer. 2018; 6(1):74. PMC: 6048712. DOI: 10.1186/s40425-018-0383-1. View

Bertotti A, Migliardi G, Galimi F, Sassi F, Torti D, Isella C . A molecularly annotated platform of patient-derived xenografts ("xenopatients") identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer. Cancer Discov. 2012; 1(6):508-23. DOI: 10.1158/2159-8290.CD-11-0109. View

Schultheis B, Reuter D, Ebert M, Siveke J, Kerkhoff A, Berdel W . Gemcitabine combined with the monoclonal antibody nimotuzumab is an active first-line regimen in KRAS wildtype patients with locally advanced or metastatic pancreatic cancer: a multicenter, randomized phase IIb study. Ann Oncol. 2017; 28(10):2429-2435. DOI: 10.1093/annonc/mdx343. View

Allen E, Jabouille A, Rivera L, Lodewijckx I, Missiaen R, Steri V . Combined antiangiogenic and anti-PD-L1 therapy stimulates tumor immunity through HEV formation. Sci Transl Med. 2017; 9(385). PMC: 5554432. DOI: 10.1126/scitranslmed.aak9679. View

Craven K, Gore J, Korc M . Overview of pre-clinical and clinical studies targeting angiogenesis in pancreatic ductal adenocarcinoma. Cancer Lett. 2016; 381(1):201-10. PMC: 4919237. DOI: 10.1016/j.canlet.2015.11.047. View

Chalmers Z, Connelly C, Fabrizio D, Gay L, Ali S, Ennis R . Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden. Genome Med. 2017; 9(1):34. PMC: 5395719. DOI: 10.1186/s13073-017-0424-2. View

Talevich E, Shain A, Botton T, Bastian B . CNVkit: Genome-Wide Copy Number Detection and Visualization from Targeted DNA Sequencing. PLoS Comput Biol. 2016; 12(4):e1004873. PMC: 4839673. DOI: 10.1371/journal.pcbi.1004873. View

Gandara D, Paul S, Kowanetz M, Schleifman E, Zou W, Li Y . Blood-based tumor mutational burden as a predictor of clinical benefit in non-small-cell lung cancer patients treated with atezolizumab. Nat Med. 2018; 24(9):1441-1448. DOI: 10.1038/s41591-018-0134-3. View

Annese T, Tamma R, Ruggieri S, Ribatti D . Angiogenesis in Pancreatic Cancer: Pre-Clinical and Clinical Studies. Cancers (Basel). 2019; 11(3). PMC: 6468440. DOI: 10.3390/cancers11030381. View

10.

Lalani A, Xie W, Martini D, Steinharter J, Norton C, Krajewski K . Change in Neutrophil-to-lymphocyte ratio (NLR) in response to immune checkpoint blockade for metastatic renal cell carcinoma. J Immunother Cancer. 2018; 6(1):5. PMC: 5776777. DOI: 10.1186/s40425-018-0315-0. View

11.

Larbouret C, Robert B, Navarro-Teulon I, Thezenas S, Ladjemi M, Morisseau S . In vivo therapeutic synergism of anti-epidermal growth factor receptor and anti-HER2 monoclonal antibodies against pancreatic carcinomas. Clin Cancer Res. 2007; 13(11):3356-62. DOI: 10.1158/1078-0432.CCR-06-2302. View

12.

Le D, Durham J, Smith K, Wang H, Bartlett B, Aulakh L . Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science. 2017; 357(6349):409-413. PMC: 5576142. DOI: 10.1126/science.aan6733. View

13.

Taylor M, Lee C, Makker V, Rasco D, Dutcus C, Wu J . Phase IB/II Trial of Lenvatinib Plus Pembrolizumab in Patients With Advanced Renal Cell Carcinoma, Endometrial Cancer, and Other Selected Advanced Solid Tumors. J Clin Oncol. 2020; 38(11):1154-1163. PMC: 7145588. DOI: 10.1200/JCO.19.01598. View

14.

Fukumura D, Kloepper J, Amoozgar Z, Duda D, Jain R . Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges. Nat Rev Clin Oncol. 2018; 15(5):325-340. PMC: 5921900. DOI: 10.1038/nrclinonc.2018.29. View

15.

Jeyakumar G, Kim S, Bumma N, Landry C, Silski C, Suisham S . Neutrophil lymphocyte ratio and duration of prior anti-angiogenic therapy as biomarkers in metastatic RCC receiving immune checkpoint inhibitor therapy. J Immunother Cancer. 2017; 5(1):82. PMC: 5646127. DOI: 10.1186/s40425-017-0287-5. View

16.

Socinski M, Jotte R, Cappuzzo F, Orlandi F, Stroyakovskiy D, Nogami N . Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC. N Engl J Med. 2018; 378(24):2288-2301. DOI: 10.1056/NEJMoa1716948. View

17.

Le D, Uram J, Wang H, Bartlett B, Kemberling H, Eyring A . PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015; 372(26):2509-20. PMC: 4481136. DOI: 10.1056/NEJMoa1500596. View

18.

McKenna A, Hanna M, Banks E, Sivachenko A, Cibulskis K, Kernytsky A . The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. Genome Res. 2010; 20(9):1297-303. PMC: 2928508. DOI: 10.1101/gr.107524.110. View

19.

Sahin I, Askan G, Hu Z, OReilly E . Immunotherapy in pancreatic ductal adenocarcinoma: an emerging entity?. Ann Oncol. 2017; 28(12):2950-2961. PMC: 5834032. DOI: 10.1093/annonc/mdx503. View

20.

Moore M, Goldstein D, Hamm J, Figer A, Hecht J, Gallinger S . Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 2007; 25(15):1960-6. DOI: 10.1200/JCO.2006.07.9525. View